FDA to Evaluate BeiGene’s Tevimbra Combination for Gastric/Gastroesophageal Junction Adenocarcinoma.

Trial data support Tevimbra combined with chemotherapy as a potential first-line treatment option for patients with locally advanced, unresectable or metastatic gastric or gastroesophageal junction cancer.

Source link
#FDA #Evaluate #BeiGenes #Tevimbra #Combination #GastricGastroesophageal #Junction #Adenocarcinoma